ribavirin

By Targets:	Antibiotic (6) Dengue Virus (1) Drug Metabolite (2) Flavivirus (1) Glucokinase (1) HBV (3) HCV (11) HIV (1) Influenza Virus (4) Isotope-Labeled Compounds (3) Nucleoside Antimetabolite/Analog (1) Orthopoxvirus (5) Reference Standards (4) RSV (9) SARS-CoV (1)
By Research Areas:	Cancer (6) Infection (19)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0434

*Ribavirin* 55+ Cited Publications Ribasphere	HCV RSV Orthopoxvirus Antibiotic	Infection Cancer
Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

HY-13317

Oseltamivir 45+ Cited Publications GS 4104	Influenza Virus	Infection Cancer
Oseltamivir (GS 4104) is an orally active influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC₅₀s of 0.67, 0.9, 1.34 and 13 nM, respectively .

HY-108842

Peginterferon alfa-2b PegIFN a-2b; Sch 54031; Sylatron; ViraferonPeg	HIV HCV	Infection Cancer
Peginterferon alfa-2b (PegIFN a-2b; Sch 54031; Sylatron; ViraferonPeg) is an immunomodulator. Peginterferon alfa-2b is a recombinant alfa-2b interferon covalently linked PEG with antiviral activity against HCV. Peginterferon alfa-2b decreases viral DNA in HIV. Peginterferon alfa-2b can be used in research of melanoma and hepatitis C .

HY-145991

Ribavirin carboxylic acid	Drug Metabolite	Infection
Ribavirin carboxylic acid (TR-COOH) is a metabolite of Ribavirin (HY-B0434), Ribavirin has strong antiviral activity .

HY-10545A

Taribavirin hydrochloride	HBV HCV	Infection
Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin hydrochloride is a Ribavirin proagent, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia .

HY-B0434R

Ribavirin (Standard) Ribasphere (Standard)	Reference Standards HCV RSV Orthopoxvirus Antibiotic	Infection Cancer
Ribavirin (Standard) is the analytical standard of Ribavirin. This product is intended for research and analytical applications. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

HY-129972

Ribavirin 5'-monophosphate dilithium RMP dilithium	Nucleoside Antimetabolite/Analog	Others
Ribavirin 5'-monophosphate dilithium is an active form of ribavirin that inhibits IMP dehydrogenase, and ribavirin itself is a broad-spectrum antiviral agent .

HY-124224

D4-Ribavirin	Dengue Virus Flavivirus	Infection
D4-Ribavirin (Compound 4) is a deoxygenated ribavirin analogue. D4-Ribavirin has antiviral property in vitro against the RNA-containing bunyaviruses–Rift Valley Fever () with an IC₅₀ of 61 μg/mL .

HY-13317R

Oseltamivir (Standard) GS 4104 (Standard)	Reference Standards Influenza Virus	Infection
Oseltamivir (Standard) is the analytical standard of Oseltamivir. This product is intended for research and analytical applications. Oseltamivir (GS 4104) is an orally active influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC₅₀s of 0.67, 0.9, 1.34 and 13 nM, respectively .

HY-B0434G

Ribavirin Ribasphere; ICN-1229	Antibiotic RSV HCV Orthopoxvirus	Infection
Ribavirin (GMP) is Ribavirin (HY-B0434) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

HY-10545

Taribavirin	HBV HCV	Infection
Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin, is a ribavirin proagent, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia .

HY-B0434S

Ribavirin-13C5 Ribasphere-¹³C₅	Isotope-Labeled Compounds HCV RSV Antibiotic	Infection
Ribavirin- ¹³C₅ is the ¹³C-labeled Ribavirin. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV.

HY-B0434S1

Ribavirin-15N, d2 ICN-1229-₁₅N, d₂	RSV Antibiotic Orthopoxvirus HCV Isotope-Labeled Compounds	Infection Cancer
Ribavirin- ¹⁵N, d2 is ¹⁵N and deuterated labeled Ribavirin (HY-B0434). Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

HY-145991R

Ribavirin carboxylic acid (Standard)	Reference Standards Drug Metabolite	Infection
Ribavirin carboxylic acid (Standard) is the analytical standard of Ribavirin carboxylic acid. This product is intended for research and analytical applications. Ribavirin carboxylic acid (TR-COOH) is a metabolite of Ribavirin (HY-B0434), Ribavirin has strong antiviral activity .

HY-W779404

Ribavirin-13C2 Ribasphere-13C₂	Isotope-Labeled Compounds RSV HCV Antibiotic Orthopoxvirus	Cancer
Ribavirin- ¹³C₂ (Ribasphere- ¹³C₂) is the ¹³C-labeled Ribavirin (HY-B0434). Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

HY-130627

RSV/IAV-IN-2	RSV Influenza Virus	Infection
RSV/IAV-IN-2 (compound 14c) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-2 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-2 has the potential for the research of RSV and/or IAV infections .

HY-130626

RSV/IAV-IN-1	RSV Influenza Virus	Infection
RSV/IAV-IN-1 (compound 14e) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-1 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-1 has the potential for the research of RSV and/or IAV infections .

HY-154966

RSV L-protein-IN-3	RSV	Infection
RSV L-protein-IN-3 is a wild-type RSV polymerase inhibitor with an IC₅₀ value of 10.4 μM and an EC₅₀ value of 2.1 μM (against RSV). RSV L-protein-IN-3 has lesser cytotoxicity than the clinical agent, Ribavirin (HY-B0434) .

HY-119415

Levovirin ICN-17261	HCV	Others
Levovirin (ICN-17261) is a potent 1-β-aminopyrazole-3-carboxamide that activates human T cells to secrete type 1 cytokines comparable to ribavirin. Levovirin shows promising immunomodulatory properties .

HY-117603

CM-10-18	Glucokinase	Infection
CM-10-18 is a potent and orally active inhibitor of both α-glucosidases I and II in vitro and in animals. CM-10-18 inhibits DENV infection of cultured human cells and reduces the peak viremia of DENV in mice .

HY-W210476

Somantadine	SARS-CoV	Infection
Somantadine, an adamantane derivative, is an antiviral agent with high cross-reactivity with anti-amantadine monoclonal antibodies. Somantadine can be used for research of coronavirus-related diseases .

HY-10545AR

Taribavirin hydrochloride (Standard)	Reference Standards HBV HCV	Infection
Taribavirin hydrochloride (Standard) is the analytical standard of Taribavirin hydrochloride (HY-10545A). This product is intended for research and analytical applications. Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin hydrochloride is a Ribavirin proagent, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library	391 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

391 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Type

HY-B0434G

Ribavirin Ribasphere; ICN-1229	Fluorescent Dye
Ribavirin (GMP) is Ribavirin (HY-B0434) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

Cat. No.	Product Name	Type

HY-B0434G

Ribavirin Ribasphere; ICN-1229	Biochemical Assay Reagents
Ribavirin (GMP) is Ribavirin (HY-B0434) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

Cat. No.	Product Name	Target	Research Area	Image

HY-108842

Peginterferon alfa-2b PegIFN a-2b; Sch 54031; Sylatron; ViraferonPeg	HIV HCV	Infection Cancer
Peginterferon alfa-2b (PegIFN a-2b; Sch 54031; Sylatron; ViraferonPeg) is an immunomodulator. Peginterferon alfa-2b is a recombinant alfa-2b interferon covalently linked PEG with antiviral activity against HCV. Peginterferon alfa-2b decreases viral DNA in HIV. Peginterferon alfa-2b can be used in research of melanoma and hepatitis C .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-129972

Ribavirin 5'-monophosphate dilithium RMP dilithium	Structural Classification Natural Products Endogenous metabolite Source Classification	Nucleoside Antimetabolite/Analog
Ribavirin 5'-monophosphate dilithium is an active form of ribavirin that inhibits IMP dehydrogenase, and ribavirin itself is a broad-spectrum antiviral agent .

Cat. No.	Product Name	Chemical Structure

HY-B0434S

Ribavirin-13C5
Ribavirin- ¹³C₅ is the ¹³C-labeled Ribavirin. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV.

HY-B0434S1

Ribavirin-15N, d2
Ribavirin- ¹⁵N, d2 is ¹⁵N and deuterated labeled Ribavirin (HY-B0434). Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

HY-W779404

Ribavirin-13C2
Ribavirin- ¹³C₂ (Ribasphere- ¹³C₂) is the ¹³C-labeled Ribavirin (HY-B0434). Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0434G

Ribavirin Ribasphere; ICN-1229	Antibiotic RSV HCV Orthopoxvirus	Infection
Ribavirin (GMP) is Ribavirin (HY-B0434) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

ribavirin

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products